Phase I Study of Cytokine Induced Memory-Like Natural Killer Cells Combined With Atezolizumb in Subjects With Relapsed or Refractory Acute Myelogenous Leukemia

Summary

The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.

Eligibility

Age range

18–70 years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  Cytokine Induced Memory-Like Natural Killer Cells

  Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.

• Biological
  Atezolizumb

  Single dose of Atezolizumab IV over 60 minutes IV.

• Biological
  CIML-NK cell therapy

  CIML-NK cell therapy as an intravenous (IV) infusion

Locations (7)